Sartor, A. O., Higano, C. S., Cooperberg, M. R., Vogelzang, N. J., Dakhil, S. R., Pieczonka, C. M., … Armstrong, A. J. (2018). Sipuleucel-T (sip-T) overall survival (OS) and clinical outcomes by baseline (BL) prostate-specific antigen (PSA) quartiles in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): PROCEED registry. In Journal of Clinical Oncology (Vol. 36, pp. 5041–5041). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2018.36.15_suppl.5041

Sartor, A Oliver, Celestia S. Higano, Matthew R. Cooperberg, Nicholas J. Vogelzang, Shaker R. Dakhil, Christopher Michael Pieczonka, Jeff Vacirca, et al. “Sipuleucel-T (sip-T) overall survival (OS) and clinical outcomes by baseline (BL) prostate-specific antigen (PSA) quartiles in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): PROCEED registry.” In Journal of Clinical Oncology, 36:5041–5041. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.5041.

Sartor AO, Higano CS, Cooperberg MR, Vogelzang NJ, Dakhil SR, Pieczonka CM, et al. Sipuleucel-T (sip-T) overall survival (OS) and clinical outcomes by baseline (BL) prostate-specific antigen (PSA) quartiles in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): PROCEED registry. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. 5041–5041.

Sartor, A. Oliver, et al. “Sipuleucel-T (sip-T) overall survival (OS) and clinical outcomes by baseline (BL) prostate-specific antigen (PSA) quartiles in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): PROCEED registry.” Journal of Clinical Oncology, vol. 36, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2018, pp. 5041–5041. Crossref, doi:10.1200/jco.2018.36.15_suppl.5041.

Sartor AO, Higano CS, Cooperberg MR, Vogelzang NJ, Dakhil SR, Pieczonka CM, Vacirca J, Concepcion RS, Tutrone RF, Nordquist LT, Olsson CA, Penson DF, Schnadig I, Bailen JL, Mehlhaff B, Chang NN, Sheikh NA, Brown B, Armstrong AJ. Sipuleucel-T (sip-T) overall survival (OS) and clinical outcomes by baseline (BL) prostate-specific antigen (PSA) quartiles in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): PROCEED registry. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. 5041–5041.